The National Cancer Institute approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10346
Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-Expressing Advanced Solid Tumors
National Cancer Institute LAO
O’Sullivan Coyne, Geraldine
(301) 402-9122
Phase I – 10367
A Phase 1b Study with Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML)
City of Hope Comprehensive Cancer Center LAO
Kelly, Kevin R.
(323) 865 3828 MTD
Phase I/II – 10366
A Phase 1/2 Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Davis, Sarah Lindsey
(303) 724-8681
Phase II – 10330
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Yale University Cancer Center LAO
Ingham, Matthew
(202) 285-4944
Phase II – 10334
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy
Yale University Cancer Center LAO
Zeidan, Amer M.
(203) 737-2572
Phase II – A091902
A Multicenter Phase II Trial of Paclitaxel with and Without Nivolumab in Taxane NaÔve, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma
Alliance for Clinical Trials in Oncology
Grilley-Olson, Juneko E.
(919) 843-5497
Phase II – AREN1921
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Children’s Oncology Group
Geller, James Ian
(513) 636-6312 X 6312
Phase II – EA6192
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
ECOG-ACRIN Cancer Research Group
Gibney, Geoffrey Thomas
(202) 444-2223
Phase II – EA8185
Phase 2 Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage 3, Node PosItive BladdeR CancEr (INSPIRE)
ECOG-ACRIN Cancer Research Group
Joshi, Monika
(717) 798-8678
Phase II/III – NRG-HN006
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
NRG Oncology
Lai, Stephen Yenzen
(713) 792-6528
Phase III – A031902
CASPAR – A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Alliance for Clinical Trials in Oncology
Rao, Arpit
(612) 625-9604
